Inhibition of Cyclic GMP ‐ AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1 ‐Deficient Mice
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Type I interferon ( IFN ) is strongly implicated in the pathogenesis of systemic lupus erythematosus ( SLE ) as well as rare monogenic interferonopathies such as Aicardi‐Goutières syndrome ( AGS ), a disease attributed to mutations in the DNA exonuclease TREX 1 . The DNA ‐activated type I IFN pathway cyclic GMP ‐ AMP ( cGAMP ) synthase ( cGAS ) is linked to subsets of AGS and lupus. This study was undertaken to identify inhibitors of the DNA – cGAS interaction, and to test the lead candidate drug, X6, in a mouse model of AGS. Methods: Trex1 −/− mice were treated orally from birth with either X6 or hydroxychloroquine ( HCQ ) for 8 weeks. Expression of IFN ‐stimulated genes ( ISG s) was quantified by quantitative polymerase chain reaction. Multiple reaction monitoring by ultra‐performance liquid chromatography coupled with tandem mass spectrometry was used to quantify the production of cGAMP and X6 drug concentrations in the serum and heart tissue of Trex1 −/− mice. Results: On the basis of the efficacy‐to‐toxicity ratio established in vitro, drug X6 was selected as the lead candidate for treatment of Trex1 −/− mice. X6 was significantly more effective than HCQ in attenuating ISG expression in mouse spleens ( P < 0.01 for Isg15 and Isg20 ) and hearts ( P < 0.05 for Isg15 , Mx1 , and Ifnb, and P < 0.01 for Cxcl10 ), and in reducing the production of cGAMP in mouse heart tissue ( P < 0.05), thus demonstrating target engagement by the X6 compound. Of note, X6 was also more effective than HCQ in reducing ISG expression in vitro ( P < 0.05 for IFI 27 and MX 1 , and P < 0.01 for IFI 44L and PKR ) in human peripheral blood mononuclear cells from patients with SLE . Conclusion: This study demonstrates that X6 is superior to HCQ for the treatment of an experimental autoimmune myocarditis mediated in vivo by the cGAS /stimulator of IFN genes ( cGAS / STING ) pathway. The findings suggest that drug X6 could be developed as a novel treatment for AGS and/or lupus to inhibit activation of the cGAS / STING pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Trex1 prevents cell-intrinsic initiation of autoimmunity
Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280 · cited 3×
“Type I IFN is convincingly implicated in the inflammatory myocarditis and early mortality observed in this mouse model, since disease manifestations were strikingly attenuated in Trex1 9 Ifnar double-knockout mice (25) and were also improved in mice treated with an inhibitor of the downstream kinase TANK-binding kinas…”
BackgroundLee-Kirsch, M. A., Gong, M., Chowdhury, D., Senenko, L., Engel, K., Lee, Y.-A., de Silva, U., Bailey, S. L., Witte, T., Vyse, T. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2091 · Cited by 730
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines
Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000702 · Cited by 606
Gall, A., Treuting, P., Elkon, K. B., Loo, Y.-M., Gale, M., Barber, G. N., & Stetson, D. B. (2012) · Immunity · doi:10.1016/j.immuni.2011.11.018 · Cited by 510 · cited 7×
“Curiously, although TREX1 deficiency in humans causes a brain phenotype characterized by spasticity, dystonia, seizures, and psychomotor retardation in childhood, the dominant clinical manifestation in Trex1 / mice is an autoimmune myocarditis (7,8).”
BackgroundMethodInfluentialSelf-citationPokatayev, V., Hasin, N., Chon, H., Cerritelli, S. M., Sakhuja, K., Ward, J. M., Morris, H. D., Yan, N., & Crouch, R. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151464 · Cited by 245
Cited by
The cGAS–STING pathway as a therapeutic target in inflammatory diseases
Decout, A., Katz, J. D., Venkatraman, S., & Ablasser, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00524-z · Cited by 2,309
TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells
Balka, K. R., Louis, C., Saunders, T. L., Smith, A. M., Calleja, D. J., D’Silva, D. B., Moghaddas, F., Tailler, M., Lawlor, K. E., Zhan, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.056 · Cited by 485
Liao, Y., Cheng, J., Kong, X., Li, S., Li, X., Zhang, M., Zhang, H., Yang, T., Dong, Y., Li, J., et al. (2020) · Theranostics · doi:10.7150/thno.47651 · Cited by 348
“For example, cGAS is activated by self-DNA in Aicardi-Goutières syndrome (AGS), and the activation of cGAS leads to severe inflammation in the brain, skin, heart, and muscle [16, 17].”
Role of the cGAS–STING pathway in systemic and organ-specific diseases
Skopelja-Gardner, S., An, J., & Elkon, K. B. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00589-6 · Cited by 307
Self-citationSmall molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Ding, C., Song, Z., Shen, A., Chen, T., & Zhang, A. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.03.001 · Cited by 306
Metadata
- Authors
- An, J., Woodward, J. J., Lai, W., Minie, M., Sun, X., Tanaka, L., Snyder, J. M., Sasaki, T., & Elkon, K. B.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2018-09-14
- Volume
- 70
- Issue
- 11
- Pages
- 1807-1819
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2803376047
- Cited by
- 130
- References
- 6
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Cyclic GMP ‐ AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1 ‐Deficient Mice. https://app.cochat.ai/papers/10.1002/art.40559
- The paper
- An, J., Woodward, J. J., Lai, W., Minie, M., Sun, X., Tanaka, L., Snyder, J. M., Sasaki, T., & Elkon, K. B. (2018). Inhibition of Cyclic GMP ‐ AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1 ‐Deficient Mice. Arthritis & Rheumatology. https://doi.org/10.1002/art.40559
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.